NEWS | BEAM Alliance


BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

Key messages

  • Antimicrobial resistance (AMR) is a global, multi-sectoral issue that affects all countries and, if unaddressed, will become one of the most formidable health crises of the century
  • Market failures and limited guidelines heavily impact the risk level associated with AMR R&D
  • Currently, SMEs are by far the largest contributors to the AMR drug pipeline. SMEs are not cash flow positive and compete with other indication fields to capture equity and non-dilutive funding
  • Funding instruments dedicated to the AMR community should be designed, in particular to move forward preclinical and clinical products, as a European complement to the CARB-X and BARDA initiatives
  • The upcoming Horizon Europe framework programme offers various opportunities to set-up such targeted instruments

Full Memo available here